Royalty Report: Drugs, Cancer, Therapeutic – Collection: 235013

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Biotechnology
  • Disease
  • Delivery
  • Cannabis
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 235013

License Grant
The Parties entered into the Licensing Agreement with Licensor, a Singapore corporation,  to, among other things, provide Licensee with an exclusive worldwide license to use the Cell-in-a-Box® Trademark and its Associated Technology.
License Property
Technology relates to genetically modified HEK293 cells overexpressing the cytochrome P450 2B1 gene specifically designed for the treatment of cancer to conduct research, to use in preclinical studies and clinical trials, to obtain marketing approval and to market and sell products and treatments utilizing the Cell-in-a-Box® Trademark and its Associated Technology world-wide.  The Parties agreed to amend the royalties, milestone and sublicensees conderations; in addition to reflect the new name and address.
Field of Use
This agreement pertains to the drug industry relating to the treatment of cancer.

IPSCIO Record ID: 93480

License Grant
The Third Addendum and the Clarification Agreement provide the company with an exclusive world-wide license, with a right to sublicense, to use the Cell-in-a-Box® technology for the development of treatments for cancer and use of the Cell-in-a-Box® trademark and its associated technology using genetically modified HEK293 cells overexpressing the cytochrome P450 2B1 gene that are encapsulated using the licensed technology.
License Property
The Technology utilizes a cellulose-based live cell encapsulation technology, referred to  as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

The Cell-in-a-Box® technology, is a means to protect, isolate, store and transport living cells.
Bac-in-a-Box involves the technology which allows living cells to be encapsulated into bio-inert polymer beads. This technology allows both living eukaryotic (e.g. stem cells) and bacterial cells (e.g. probiotics) to be encapsulated in order to protect, store, isolate and transport them.

Field of Use
This agreement pertains to the medical drug industry relating to treatments for cancer.

IPSCIO Record ID: 28774

License Grant
The Singapore Licensor grants to Licensee on a worldwide basis an exclusive royalty-bearing License to the Cell-in-a-Box® Trademark and its Associated Technology, with the right to subLicense in accordance.
License Property
Cell-in-a-Box® registered trademark No. 85307295

The Technology utilizes a cellulose-based live cell encapsulation technology, referred to  as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

The Licensed rights enable Licensee to develop the use of encapsulated products to obtain a Biologics License Application, marketing approval, or its equivalent in other territories and to eventually sell and offer for sale the Products or otherwise use the Licensed Rights on a worldwide basis as described and provided for within the Scope of this Agreement.

Licensor has developed a unique and versatile cell encapsulation technology using cellulose sulphate and derivatives that can be applied to a wide range of applications – Cell-in-a-Box® Trademark and its Associated Technology.

Living cell encapsulation or the Cell-in-a-Box® technology enables living cells to be used as a miniature factory in which cells can be grown and maintained, or desired components can be created or converted for treatment of diseases or isolating products for subsequent marketing.
One of the key uses of our technology is in the treatment of solid tumors where the ability to release the active agent directly at the source of the disease facilitates localized or systemic treatment as needed, thus having the value of increasing efficacy as the treatment agent is delivered directly to the critical site. Increased efficacy can also allow for lower dosages, thereby reducing side effects. The technology also holds great potential for the treatment of systemic diseases, including but not limited to diabetes.

Field of Use
The Licensee has interest in developing therapies for the treatment of diabetes with genetically modified or non-modified non-stem cell lines and IPS stem cells specifically designed to produce insulin or other critical components for the treatment of diabetes, to research, have made by Licensor, use in clinical trials, obtain market approval, market and sell products and treatments utilizing the Cell-in-a-Box® Trademark and its Associated Technology world-wide.

IPSCIO Record ID: 28277

License Grant
Licensor, a Singapore corporation, hereby grants to Licensee on an exclusive worldwide royalty-bearing license to use the Cell-in-a-Box® Trademark and its Associated Technology with genetically modified non-stem cell lines which are designed to activate members of the cannabinoid family of molecules derived from Cannabis ('Cannabinoids') with the right to sublicense in accordance of this Agreement.  This license is granted to: conduct research; have made by Licensor; use in preclinical studies and clinical trials; obtain Marketing Approval; and market and sell Products and treatments utilizing the Cell-in-a-Box® Trademark and its Associated Technology with Cannabinoids.
License Property
Licensor has developed a unique and versatile cell encapsulation technology using cellulose sulphate and derivatives that can be applied to a wide range of applications

'Cell-in-a-Box® Trademark and its Associated Technology' refers to United States registered trademark No. 85307295.

'Associated Technology' shall mean technologies marketed under the Cell-in-a-Box® registered trademark which enable encapsulation of live eukaryotic cells placed in a polymer where one constituent of the encapsulation material is cellulose sulphate or a derivative thereof and shall include any derivative or further development of these technologies.

Field of Use
Licensee has interest in developing therapies involving Cannabis, including the activation of Cannabinoids (defined below) for the treatment of diseases and related symptoms.

Licensee has interest in developing therapies involving Cannabis, including the activation of Cannabinoids for the treatment of diseases and related symptoms including the treatment of all diseases and medical conditions, including, but not limited to, pain, diabetes, cancer, other oxidation-associated diseases and all forms of mental illness.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.